Drugs / FABOMOTIZOLE
FABOMOTIZOLE
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT04598867 Comparator | Dec 2020 → May 2023 | generalized anxiety disorder | ChemRar Research and Development Institute, LLC | Unknown | No outcome recorded |
| Phase 4 | NCT06843044 Comparator | Jan 2025 → Dec 2027 expected | adjustment disorder, anxiety, neurocirculatory asthenia | Valenta Pharm JSC | Recruiting | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FABOMOTIZOLE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3707307 ↗ |
| Known as | Afobazol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04598867 ↗ |
| Known as | Afobazole | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06843044 ↗ |
| Known as | Aphobazole | ChEMBL registry synonym — accepted as the source's own label CHEMBL3707307 ↗ |
| Known as | CM-346 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3707307 ↗ |
| Known as | Fabomotizol | ChEMBL registry synonym — accepted as the source's own label CHEMBL3707307 ↗ |
| Known as | Obenoxazine | ChEMBL registry synonym — accepted as the source's own label CHEMBL3707307 ↗ |
| Modality | Small molecule | — CHEMBL3707307 ↗ |